.

● Live

Customize

You are here

Lupin gains on getting USFDA’s nod for Trientine Hydrochloride Capsules USP

  • May-22-2020
  • 14 Hrs IST

Lupin is currently trading at Rs. 896.90, up by 11.15 points or 1.26% from its previous closing of Rs. 885.75 on the BSE.

The scrip opened at Rs. 881.10 and has touched a high and low of Rs. 897.70 and Rs. 875.60 respectively. So far 49768 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 906.35 on 27-Apr-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 897.55 and Rs. 833.80 respectively. The current market cap of the company is Rs. 40243.06 crore.

The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 39.23% and 13.85% respectively.

Lupin has received approval for its Trientine Hydrochloride Capsules USP, 250 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Syprine Capsules, 250 mg, of Bausch Health US, LLC. The product would be manufactured at Lupin’s Nagpur (Unit 1) facility, India.

Trientine Hydrochloride Capsules USP, 250 mg, are indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.